The result: your own immune system destroys your remaining pigment cells, spreading the white patches further
Much of the evidence comes from laboratory and animal studies, so benefits in humans are not guaranteed
Moderate-certainty evidence demonstrated that GLP-1 agonists probably decreased the risk of four-point major adverse cardiovascular events (composite outcome including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or need for hospitalization or coronary revascularization for unstable angina pectoris or heart failure) compared with placebo over a median 200 weeks of follow-up (risk ratio = 0.77
Cost-wise, compounded semaglutide at $199-$299/month through Omzo is substantially less than FDA-approved Ozempic or Wegovy at retail prices exceeding $1,000/month
Food, beverages other than water, and other oral medications all interfere with SNAC's buffering capacity
A medication review should also address less common but clinically important risks